Health Care/Hospital

Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB

AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...

2024-03-25 08:04 568

Veeva Vault EDC Surpasses 1,000 Study Start Milestone

Eight of the top 20 biopharmas standardize on Vault EDC to build a modern clinical data foundation SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more tha...

2024-03-25 08:00 1114

From Guangzhou to the World: Onuge Group showcase of Innovation and Quality at Cosmoprof Bologna 2024

GUANGDONG, China, March 23, 2024 /PRNewswire/ -- The Cosmoprof Bologna, a premier B2B beauty event with a legacy spanning over half a century, Founded in 1967. Once again hosted the Cosmoprof of the global beauty industry fromMarch 21st to 24th, 2024. Organized by the Bologna Exhibition Group, th...

2024-03-23 16:11 2246

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...

2024-03-22 19:00 3224

Duyun Maojian tea forest enters spring harvest season in China's Guizhou

DUYUN, China, March 22, 2024 /PRNewswire/ -- Duyun Maojian tea leaves mainly grow in Duyun City, Bouyei-Miao Autonomous Prefecture of Qiannan, southwest China's Guizhou Province. In history, they were used as a tribute to the imperial court and given the name "fish hook tea" since dried tea leaves...

2024-03-22 18:59 2838

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine

SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...

2024-03-22 18:42 2360

Frost & Sullivan Launches the 2024 Edition of India Manufacturing Excellence and Sustainability 4.0 Awards

~Nominations are open until March 31, 2023~ ~Award ceremony to be held on December 13, 2024~ MUMBAI, India, March 22, 2024 /PRNewswire/ -- Frost & Sullivan proudly announces the launch of its prestigious awards ceremonies- the15th edition of the Sustainability 4.0 Awardsand the 20th edition of th...

2024-03-22 18:30 1712

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...

2024-03-22 18:00 4934

Zylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability

HANGZHOU, China, March 22, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market inChina, announced its annual financial results for 2023. The report underlines a year of remarkable ...

2024-03-22 17:14 2281

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced that it has dosed the first patient with Atopic Dermatitis (AD) in a Phase Ⅲ ...

2024-03-22 08:00 1776

NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy

SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...

2024-03-22 08:00 1791

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...

2024-03-21 22:44 3107

Ping An Reports RMB117,989 million of Operating Profit Attributable to Shareholders of the Parent Company in 2023, cash dividend increased for 12 consecutive years

Life Insurance Rebounded with Life & Health NBV Growing 36.2% HONG KONG and SHANGHAI, March 21, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) today announced its financial results for the year end...

2024-03-21 21:10 3744

100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer

SAN FRANCISCO, March 21, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their key...

2024-03-21 20:30 1055

FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

PANGYO, South Korea, March 21, 2024 /PRNewswire/ -- Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP). Oscotec has successfully completed phase 2 study in patients wit...

2024-03-21 20:00 1226

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...

2024-03-21 19:47 2888

Biosion to Present Three Posters at the 2024 AACR Meeting

NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an anti-CD16a monoclonal antibody, BSI-730, a HER2/PD-L1 bispec...

2024-03-21 19:00 1034

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update

* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. * Anticip...

2024-03-21 19:00 1044

More Middle-Aged and Older Men Are Seeking Male Breast Reduction In Singapore, says Dr Ivan Puah

The mean age of men seeking gynecomastia surgery at Amaris B. Clinic Singapore was 33. However, recent years have witnessed a notable increase in older male patients above 42, with the oldest being 70.  SINGAPORE, March 21, 2024 /PRNewswire/ -- Dr Ivan Puah, a Singapore MOH-accredited liposuctio...

2024-03-21 18:08 1409
1234567 ... 802

Week's Top Stories